2019 American Transplant Congress
Natural Antibodies and Left Ventricular Assist Device Complications
*Purpose: Left ventricular assist devices (LVAD) are used as a bridge to heart transplantation or destination therapy for advanced heart failure. For all its benefits,…2019 American Transplant Congress
5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients
1U of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: Renal transplant (RT) after desensitization (DS) has been associated with increased rejection rates. Proteasome inhibitor(PI)-based DS yields significant reductions in HLA Ab among sensitized…2019 American Transplant Congress
Post-Transplant Anti- A Titer >1:128 in A2-Incompatible Kidney Recipients is Associated with Subclinical Antibody Mediated Rejection
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Decreased antigen expression among blood group A, subtype 2 (A2), donor kidneys allows these kidneys to be considered as universal donor kidneys and under…2019 American Transplant Congress
Successful Kidney Transplantation of Highly Sensitized Candidates across Positive Cross Match and Strong Donor-Specific HLA-DP Antibodies without Desensitization
*Purpose: Over 50% of kidney transplant (Ktx) candidates with 100% CPRA display HLA-DP antibodies, which impair the chances of finding a compatible deceased donor (DD)…2019 American Transplant Congress
Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation
*Purpose: According to the latest Banff’s criteria approved in 2003, antibody mediated rejections following renal transplantation are divided into 2 types namely C4d + and…2019 American Transplant Congress
Reduction of Circulating DSA: Does It Affect Histology?
*Purpose: De novo donor specific antibodies (dnDSA) are reported in 13-30% of kidney transplant recipients. dnDSA has been associated with antibody mediated rejection (AMR) and…2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…2019 American Transplant Congress
Solving Target Recognition and Activation Mediated by Non-HLA Agonistic Antibodies Targeting ETAR
*Purpose: Endothelin-1 type A receptor (ETAR) exhibits multiligand binding abilities and may signal upon natural ligand Endothelin-1 (ET-1) and non-HLA ETAR-agonistic IgG (ETAR-IgG)-mediated stimulation similar…2019 American Transplant Congress
Development of Non-Human Leukocyte Antigen Antibodies in Cardiac Antibody-Mediated Rejection
*Purpose: Antibody-mediated rejection (AMR), mainly driven by the development of donor-specific antibodies (DSA) directed against mismatched donor class I and class II HLA, is a…2019 American Transplant Congress
Desensitization Using Only Polyvalent Immunoglobulins (IVIG) for Kidney Transplantation with Living Donors (LD)
*Purpose: HLA sensitization is a barrier for kidney transplantation. Sensitized patients stay longer on the waiting list and have higher mortality rate and complications while…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 57
- Next Page »